ACE inhibitors, ARBs, Direct Renin inhibitors, Statins, Tetracyclines, NSAIDs
Brief exposure and teratogenic outcomes
Women can be reassured if they’ve had brief exposure to certain medications during pregnancy, that they would not be considered teratogenic, not intended to encourage use
Pregnancy and Lactation Labeling Final Rule (PLLR)
Purpose of new PLLR is to assist healthcare providers in assessing benefit versus risk
Pregnancy: includes labor and delivery
Lactation: includes nursing mothers
Females and Males of reproductivepotential
Define pregnancy exposure registries
Collect health information from women who take medicines and vaccines when they are pregnant and breastfeeding
Information is also collected on newbornbaby
Information collected is compared with women who have not taken medicine during pregnancy
Previous risk categories in pregnancy
A: Adequate, well controlled studies reveal NO RISK to fetus during first trimester
B: Animal reproduction studies have failed to demonstrate a risk to the fetus and there are no adequate and well-controlled studies in pregnant women.
C: Animal reproduction studies have shown an adverse effect on the fetus and there are no adequate and well-controlled studies in humans, but potential benefits may warrant use of the drug in pregnant women despite potential risks.
Previous risk categories in pregnancy
D: There is positive evidence of human fetal risk based on adverse reaction data from investigational or marketing experience or studies in humans, but potential benefits may warrant use of the drug in pregnant women despite potential risks.
X: Studies in animals or humans have demonstrated fetal abnormalities and/or there is positive evidence of human fetal risk based on adverse reaction data from investigational or marketing experience, and the risks involved in use of the drug in pregnant women clearly outweigh potential benefits.